EUCTR2015-005629-38-Outside-EU/EEA进行中（未招募）不适用
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 420
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •An individual must fulfill all of the following criteria in order to be eligible for trial enrollment:
- •1) Subject is 11 to < 13 years of age at the time of vaccination.
- •2) Received exactly 5 doses of pertussis vaccine at < 7 years of age.
- •3) Informed consent and assent forms have been signed and dated.
- •4) Subject is able to attend all scheduled visits and to comply with all trial procedures.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 420
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •An individual fulfilling any of the following criteria is to be excluded from trial enrollment:
- •1) Subject is pregnant, or lactating, or of child bearing potential without using an effective method of contraception or not practicing abstinence for at least 4 weeks prior to vaccination and until at least 4 weeks after vaccination.
- •2) Any condition that, in the opinion of the Investigator, would pose a health risk to the participant or interfere with the evaluation of the vaccine.
- •3) Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.
- •4) Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks) within the past 3 months).
- •5) Known or suspected receipt of any whole-cell pertussis-containing vaccine.
- •6) A personal history of physician-diagnosed or laboratory-confirmed pertussis disease within the last 2 years.
- •7) A previous severe reaction to pertussis, diphtheria or tetanus vaccine including immediate anaphylaxis, encephalopathy within 7 days, or seizure within 3 days of receiving the vaccine.
- •8) Receipt of immune globulins, blood or blood-derived products in the past 3 months.
- •9) Suspected or known hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances.
- •10) Receipt of any vaccine within 30 days before receiving study vaccine, or plans to receive another vaccine before the 2nd visit; except that influenza vaccine may have been received between 30 and 15 days (but no less than 15 days) before receiving study vaccine.
- •11) Participation in another interventional clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 30 days preceding the first study vaccination or during the course of the study, at the discretion of the Sponsor.
- •12) Seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C, as reported by the subject's parent/guardian.
- •13) Laboratory-confirmed thrombocytopenia, which may be a contraindication for IM vaccination, at the discretion of the Investigator.
- •14) Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding inclusion, which may be a contraindication for IM vaccination, at the discretion of the Investigator.
- •15) Personal history of Guillain-Barré syndrome.
- •16) Moderate or severe acute illness/infection (according to Investigator judgment) or febrile illness (temperature = 38.0°C [= 100.4°F]) on the day of vaccination. (A prospective subject should not be enrolled in the study until the condition has resolved or the febrile event has subsided.)
- •17) Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study.
- •18) Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.
- •19) Current alcohol or drug use that, in the opinion of the Investigator, might interfere with the ability t
研究者
相似试验
已完成
4 期
Immunogenicity of Adacel® and BOOSTRIX® Vaccines in AdolescentsPertussisWhooping CoughTetanusDiphtheriaNCT01629589Sanofi Pasteur, a Sanofi Company423
已完成
4 期
Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®PertussisTetanusDiphtheriaNCT00319553Sanofi647
进行中（未招募）
不适用
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Sanofi Pasteur's Dengue Vaccine in Healthy Toddlers Aged 15 to 18 Months in MexicoPrevention of symptomatic dengue diseaseEUCTR2014-001736-11-Outside-EU/EEASanofi Pasteur SA732
进行中（未招募）
不适用
Safety and Immunogenicity of Booster Vaccination with PEDIACEL®, a Combined Diphtheria, Tetanus, Five Component Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus Influenzae Type b Conjugate Vaccine (Adsorbed), Compared to Booster Vaccination with Infanrix® hexa when Both Vaccines Are Co-Administered with Prevenar® to Toddlers 11-18 Months of AgePEDIACEL is a fully liquid combination vaccine indicated for infants and children for the prevention of five infectious diseases (diphtheria, tetanus, pertussis, poliomyelitis and infections caused by Haemophilus influenzae type b), as a booster dose administered to toddlers previously primed with three doses of a hexavalent vaccine.EUCTR2006-000898-30-DESanofi Pasteur Incorporated
已完成
2 期
MEÑIQUE StudyCOVID-19SARS-CoV2Disease PreventionCoronavirus InfectionsSARS VirusCoronaviridae InfectionsBetacoronavirusRPCEC00000390Center for Genetic Engineering and Biotechnology (CIGB), in Havana.703